Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>LncRNA <em>TBX5-AS1</em> Regulates the Tumor Progression Through the PI3K/AKT Pathway in Non-Small Cell Lung Cancer</p>
QU Qing-hai, Shui-Zheng Jiang, Xinying Li
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 7949-7961
Open Access | Times Cited: 21

Showing 21 citing articles:

Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling
Maliheh Entezari, Maryam Ghanbarirad, Afshin Taheriazam, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112963-112963
Open Access | Times Cited: 81
Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application
Éva Márton, Alexandra Varga, Dóra Domoszlai, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 579-579
Open Access | Times Cited: 1
Prominin 2 knockdown inhibits the growth, migration, and invasion of non-small cell lung cancer cells by repressing phosphatidylinositol 3 kinase/protein kinase B pathway
Biao He, Zhiyuan Chen, Liang Zhong, et al.
CytoJournal (2025) Vol. 22, pp. 21-21
Open Access
Beyond the genome: lncRNAs as regulators of the PI3K/AKT pathway in lung cancer
Waleed Hassan Almalki
Pathology - Research and Practice (2023) Vol. 251, pp. 154852-154852
Closed Access | Times Cited: 10
A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction
Xuegang Niu, Jiangnan Sun, Lingyin Meng, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 25
Enhancer RNA (eRNA) in Human Diseases
Yunzhe Wang, Chenyang Zhang, Yuxiang Wang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11582-11582
Open Access | Times Cited: 15
Knockdown of SNORA47 Inhibits the Tumorigenesis of NSCLC via Mediation of PI3K/Akt Signaling Pathway
Huiqing Yu, Ling Tian, Liejun Yang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 16
Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma
Liying Yu, Shuang Zhou, Wencong Hong, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma
Lin Cheng, Tong Han, Bolin Chen, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 14
Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma
Jie Zhao, Guangjian Li, Guangqiang Zhao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: recent insights and potential clinical applications
Mehrdad Hashemi, Asal Abolghasemi Fard, Bita Pakshad, et al.
Non-coding RNA Research (2024) Vol. 11, pp. 1-21
Open Access | Times Cited: 1
NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway
Yiping Wang, Baolan Wang, Liqun Zhou, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 12, pp. 5680-5696
Closed Access | Times Cited: 1
Long Noncoding RNA LINC01554 Inhibits the Progression of NSCLC Progression by Functioning as a ceRNA for miR-1267 and Regulating ING3/Akt/mTOR Pathway
Zizong Wang, Bin Yang, Jin Zhang, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-16
Open Access | Times Cited: 7
Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma
Cheng Zeng, Huayi Yu, Xiuling Liu, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-31
Open Access | Times Cited: 7
Role of T‐box genes in cancer, epithelial‐mesenchymal transition, and cancer stem cells
Gengle Niu, Jin Hao, Surui Sheng, et al.
Journal of Cellular Biochemistry (2021) Vol. 123, Iss. 2, pp. 215-230
Closed Access | Times Cited: 9
A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma
Li Wang, Shao-Quan Zhou, Yu Zhou, et al.
Journal of Immunology Research (2022) Vol. 2022, pp. 1-18
Open Access | Times Cited: 6
Antineoplastic effects of erufosine on small cell and non-small cell lung cancer cells through induction of apoptosis and cell cycle arrest
Hüseyin Abdik
Molecular Biology Reports (2022) Vol. 49, Iss. 4, pp. 2963-2971
Closed Access | Times Cited: 5
Gender specific eRNA TBX5-AS1 as the immunological biomarker for male patients with lung squamous cell carcinoma in pan-cancer screening
Tao Yan, Kai Wang, Qidi Zhao, et al.
PeerJ (2021) Vol. 9, pp. e12536-e12536
Open Access | Times Cited: 7
Non-coding mutations at enhancer clusters contribute to pancreatic ductal adenocarcinoma
Minal Patel, Eleni Maniati, Santosh S. Atanur, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
ID2 inhibits lung adenocarcinoma cell malignant behaviors by inhibiting the activation of the PI3K/AKT/mTOR signaling pathway
Wenzhong Peng, Jia Chen, Ruoxi He, et al.
Tissue and Cell (2022) Vol. 79, pp. 101950-101950
Closed Access | Times Cited: 1
Non-coding mutations at enhancer clusters contribute to pancreatic ductal adenocarcinoma
Jun Wang, Minal Patel, Eleni Maniati, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top